The present invention provides vaccine kits and a method for vaccination using such vaccination kits.

The present invention provides vaccine kits and a method for vaccination using such vaccination kits.

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

The present invention relates to a composition comprising a) at least one oil phase, b) at least one aqueous phase, c) at-least one emulsifier, wherein the at-least one emulsifier is any or combination of at-least one emulsifier agent, water with emulsification properties, oil with emulsification properties, and active ingredient with emulsification properties; and d) optionally, one or more biologically active ingredients. The present invention also relates to use of the composition for personal care, pet care, home care, deodorants, pesticides, moisturizers, disinfectants, cleansers, therapeutic devices, topical supplements and/or nutrition. The present invention also relates to a method for preparing such a composition.

The present invention relates to a composition comprising a) at least one oil phase, b) at least one aqueous phase, c) at-least one emulsifier, wherein the at-least one emulsifier is any or combination of at-least one emulsifier agent, water with emulsification properties, oil with emulsification properties, and active ingredient with emulsification properties; and d) optionally, one or more biologically active ingredients. The present invention also relates to use of the composition for personal care, pet care, home care, deodorants, pesticides, moisturizers, disinfectants, cleansers, therapeutic devices, topical supplements and/or nutrition. The present invention also relates to a method for preparing such a composition.

The present invention relates to the Lactobacillus helveticus VF45A strain, mutants and variants thereof capable of reducing the pH of milk to about 3.36 or less after 48 hours of fermentation. The present invention also relates to isolated peptides that may be obtained by fermentation of milk by the aforementioned strain. The present invention also relates to the Lactobacillus helveticus VFH049 strain and mutants and variants thereof capable of producing at least one peptide corresponding to the SEQ ID 44 to SEQ ID NO 86 sequences and/or capable of increasing the intestinal absorption of calcium. The present invention also relates to an isolated peptide and associated products and compositions and the Lactobacillus delbrueckii ssp. bulgaricus VF50b strain and mutants and variants thereof capable of producing at least one peptide corresponding to the SEQ ID 87 to SEQ ID NO 199 sequences and/or capable of increasing the intestinal absorption of calcium.

The present invention relates to the Lactobacillus helveticus VF45A strain, mutants and variants thereof capable of reducing the pH of milk to about 3.36 or less after 48 hours of fermentation. The present invention also relates to isolated peptides that may be obtained by fermentation of milk by the aforementioned strain. The present invention also relates to the Lactobacillus helveticus VFH049 strain and mutants and variants thereof capable of producing at least one peptide corresponding to the SEQ ID 44 to SEQ ID NO 86 sequences and/or capable of increasing the intestinal absorption of calcium. The present invention also relates to an isolated peptide and associated products and compositions and the Lactobacillus delbrueckii ssp. bulgaricus VF50b strain and mutants and variants thereof capable of producing at least one peptide corresponding to the SEQ ID 87 to SEQ ID NO 199 sequences and/or capable of increasing the intestinal absorption of calcium.

The present invention relates to vitamin D.sub.3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.

##STR00001##

The present invention relates to vitamin D.sub.3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.

##STR00001##

An enhanced bone graft product includes a host matrix, a bone graft material, a scaffold, or a biological construct, and a composition including a therapeutically effective amount of protocatechuic acid. The bone graft material may be autographic, allographic, alloplastic, or xenographic. The bone graft material may include fresh bone, freeze-dried bone, or demineralized freeze-dried bone. The composition may include a pharmaceutically acceptable carrier, adjuvant, or vehicle. The composition may include protocatechuic acid at a concentration of about 10 μM to about 250 μM. The composition may further include mesenchymal stem cells, adipose tissue-derived stem cells, endothelial progenitor cells, mesenchymal skeletal stem cells, synovial stem cells, bone marrow extract, osteoblasts, chondrocytes, osteocytes, or combinations thereof.